Bronchial Asthma and Diabetes: Impact on Bronchial Inflammation and Exercise Capacity
Key facts
- Who runs it
- Istituti Clinici Scientifici Maugeri SpA
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 39 people enrolled
- Started
- 10 Jul 2019
- Ended
- 12 Jan 2024
- Type of study
- Observational, 3 groups
- Treatments tested
- data collection
- Record updated
- 8 February 2024
- Why it stopped
- technical issue
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Diagnosis of bronchial asthma according to the GINA 2018 guideline
- Clinical stability of asthmatic disease
- Diagnosis of Type II diabetes according to the last Italian guidelines (1) and HbA1c < 9%, 54-75mmol/mol
- Concomitant diagnosis of bronchial asthma (12) and diabetes according to the described guidelines
- Age ≥18 years
- Not-smokers, smokers or ex-smokers with pack/year ≤10
- Patients able to collaborate in the required procedures and who have signed the informed consent
Who cannot take part
- Bronchial asthma and/or diabetes with scarce clinical control
- Diagnosis of cognitive impairment
- Not able to carry out study procedures
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Type 2 diabetes is the most common form of diabetes and according to several studies, even lung can represent another target of the diabetic disease. Asthmatic patients often show comorbidities and obesity is one of the main.Several studies in literature suggest that patients with higher Body Mass Index (i.e. overweight and obese) have a greater risk of developing asthma compared to normal weight subjects. Considering inflammation, asthma is usually characterized by an increase of eosinophils in the airways and by a Th2 type inflammation, while a immunological type Th1 switch systemically characterizes diabetes. Even asthmatic patients, especially if diabetic, might have an increase of glucose in their airways, that could favourite or feed an inflammatory/infective state. Up to-day there are not in literature studies that have investigated the airways inflammatory pattern and the exercise capacity in relation to functional characteristics in diabetic patients affected by asthma.
The 3 groups in the trial
- G1 Asthma
Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
Treatment: data collection
- G2 Diabetes
Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c \< 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
Treatment: data collection
- G3 Asthma plus diabetes
Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c \< 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
Treatment: data collection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 February 2024